BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1225 related articles for article (PubMed ID: 17313562)

  • 1. Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
    Okumura H; Yamaguchi M; Kotani T; Sugimori N; Sugimori C; Ozaki J; Kondo Y; Yamazaki H; Chuhjo T; Takami A; Ueda M; Ohtake S; Nakao S
    Eur J Haematol; 2007 Feb; 78(2):157-60. PubMed ID: 17313562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
    Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of donor lymphocyte infusions following mismatched stem cell transplantation.
    Or R; Hadar E; Bitan M; Resnick IB; Aker M; Ackerstein A; Samuel S; Tsirigotis P; Gesundheit B; Slavin S; Shapira MY
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1295-301. PubMed ID: 17162211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors.
    Teshima T; Matsuo K; Matsue K; Kawano F; Taniguchi S; Hara M; Hatanaka K; Tanimoto M; Harada M; Nakao S; Abe Y; Wake A; Eto T; Takemoto Y; Imamura M; Takahashi S; Ishida Y; Kanda Y; Kasai M; Takaue Y
    Br J Haematol; 2005 Aug; 130(4):575-87. PubMed ID: 16098073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
    Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF
    N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
    Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
    Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
    Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
    Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
    Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
    Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
    Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Application of FBC conditioning regimen in HLA haplotype peripheral blood stem cell transplantation].
    Wu B; Guo K; Song Z; Yan D; Yang Y; Xiao L
    Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):194-7. PubMed ID: 12133456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recipients of HLA-identical sibling marrow transplants with severe aplastic anemia engraft more quickly, and those with chronic myeloid leukemia more slowly, than those with acute leukemia.
    Atkinson K; Downs K; Ashby M; Dodds A; Concannon A; Biggs J
    Bone Marrow Transplant; 1989 Jan; 4(1):23-7. PubMed ID: 2647183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation from related and unrelated donors for aplastic anaemia in adults--a single-centre experience.
    Buchholz S; Dammann E; Koenecke Ch; Stadler M; Franzke A; Blasczyk R; Bremer M; Krauter J; Hertenstein B; Ganser A; Eder M
    Ann Hematol; 2008 Jul; 87(7):551-6. PubMed ID: 18386010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience.
    Gómez-Almaguer D; Vela-Ojeda J; Jaime-Pérez JC; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Sobrevilla-Calvo P; Rivas-Vera S; Gómez-Rangel JD; Ruiz-Argüelles GJ
    Am J Hematol; 2006 Mar; 81(3):157-61. PubMed ID: 16493614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified haploidentical nonmyeloablative transplantation without T cell depletion for high-risk acute leukemia: successful engraftment and mild GVHD.
    Guo M; Sun Z; Sun QY; Han Q; Yu CL; Wang DH; Qiao JH; Chen B; Sun WJ; Hu KX; Liu GX; Liu B; Zhao RC; Ai H
    Biol Blood Marrow Transplant; 2009 Aug; 15(8):930-7. PubMed ID: 19589482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second transplant with two unrelated cord blood units for early graft failure after haematopoietic stem cell transplantation.
    Fernandes J; Rocha V; Robin M; de Latour RP; Traineau R; Devergie A; Ribaud P; Réa D; Larghero J; Gluckman E; Socié G
    Br J Haematol; 2007 May; 137(3):248-51. PubMed ID: 17408466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
    Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
    Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.